MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) presented new obesity and metabolic data at ADA 2026. Phase 1 48 mg DA-1726 achieved 9.1% mean body weight reduction by Day 54, with notable waist and BMI decreases and generally mild-to-moderate GI events. Preclinical vanoglipel combinations with resmetirom and metformin showed synergistic weight loss, liver marker and glycemic improvements in mouse models, supporting potential combination strategies in MASH, T2D and obesity.

Positive

• DA-1726 48 mg cohort achieved 9.1% mean body weight reduction at Day 54
• Waist circumference decreased 9.8 cm and BMI fell 3.4 kg/m² by Day 54 with DA-1726
• DA-1726 generally well tolerated with no treatment-related discontinuations or serious adverse events
• Vanoglipel plus resmetirom cut body weight 23.6% versus control in MASH mouse model
• Vanoglipel plus resmetirom reduced ALT up to 83.5% with improved liver histology markers
• Vanoglipel plus metformin lowered non-fasting glucose 28.7% and fasting glucose 22.7% versus control
• Vanoglipel plus metformin achieved 16.3% body weight reduction versus control and 25.6% fat-mass drop from baseline

Negative

• None.

News Market Reaction – MTVA

-13.62%

49 alerts

-13.62% Session close to close

-42.3% Trough in 13 hr 41 min

$13.27M Market Cap

0.0x Rel. Volume

In the Jun 8 session, MTVA declined 13.62%, reflecting a significant negative market reaction. Argus tracked a trough of -42.3% from its starting point during tracking. Our momentum scanner triggered 49 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -13.6% in the session following this news. A negative reaction despite detailed AD...

Analysis

The stock dropped -13.6% in the session following this news. A negative reaction despite detailed ADA 2026 data would fit a pattern where some neutral-to-positive updates, including conferences and earnings, saw pressure even as the pipeline advanced. The stock remained far below its $19.03 52-week high, and recent filings cited “substantial doubt” about going concern, underscoring financing risk. In that context, investors may have focused more on balance-sheet constraints than on incremental DA-1726 and vanoglipel signals.

Key Figures

Weight loss Day 54: 9.1% Weight loss Day 26: 6.1% Waist reduction Day 54: 9.8 cm +5 more

8 metrics

Weight loss Day 54 9.1% DA-1726 48 mg Phase 1 cohort, body weight reduction at Day 54

Weight loss Day 26 6.1% DA-1726 48 mg Phase 1 cohort, body weight reduction at Day 26

Waist reduction Day 54 9.8 cm DA-1726 48 mg Phase 1 cohort, waist circumference change at Day 54

BMI reduction Day 54 3.4 kg/m² DA-1726 48 mg Phase 1 cohort, BMI change at Day 54

Combo weight loss 23.6% Vanoglipel + resmetirom combo, body weight reduction vs control in MASH model

ALT reduction combo 83.5% Vanoglipel + resmetirom combo, largest ALT reduction rate

Non-fasting glucose drop 28.7% Vanoglipel + metformin, non-fasting glucose reduction vs control

Combo weight loss T2D model 16.3% Vanoglipel + metformin, body weight reduction vs control

Historical Context

5 past events · Latest: 2026-06-04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
2026-06-04	Conference preview	Neutral	-8.6%	Announcement of Emerging Growth Conference pipeline presentation and webcast details.
2026-05-27	Clinical trial data	Positive	+12.5%	Higher-dose Phase 1 DA-1726 results with 9.1% weight and 9.8 cm waist reductions.
2026-05-20	Preclinical publication	Positive	+47.9%	Peer-reviewed data supporting vanoglipel’s anti-fibrotic potential and biomarker improvements.
2026-05-18	Conference acceptance	Neutral	+0.0%	Acceptance of three ADA 2026 late-breaking posters on DA-1726 and vanoglipel.
2026-05-14	Earnings & update	Neutral	-6.7%	Q1 2026 financials with DA-1726 progress and cash runway into Q4 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical or mechanistic updates for DA-1726 and vanoglipel have often coincided with strong gains, while conferences and earnings-related items have sometimes seen negative reactions.

Recent Company History

Over the last few months, MetaVia has steadily highlighted its cardiometabolic pipeline. On May 27, 2026, higher-dose Phase 1 DA-1726 data with 9.1% weight loss and waist reductions at Day 54 was followed by a 12.46% move. A May 20 peer-reviewed vanoglipel publication coincided with a 47.9% gain, underscoring market focus on MASH and metabolic assets. In contrast, conference previews on May 18 and an earnings and corporate update on May 14 saw flat to negative reactions. Today’s ADA 2026 poster data extends the same DA-1726 and vanoglipel story with additional detail and confirmation.

Key Terms

metabolic dysfunction-associated steatohepatitis, glp1r, gcgr, gpr119, +2 more

6 terms

metabolic dysfunction-associated steatohepatitis medical

"combination treatment potential for vanoglipel (DA-1241)... in metabolic dysfunction-associated steatohepatitis (MASH)"

Metabolic dysfunction-associated steatohepatitis is a liver disease in which fat buildup tied to metabolic problems such as obesity and diabetes leads to inflammation and scarring, like rust forming inside a machine that gradually impairs function. It matters to investors because its growing prevalence creates large markets for drugs, diagnostics and care, and clinical trial results, approvals, or reimbursement decisions can sharply change the value of healthcare companies working in this area.

glp1r medical

"a novel dual agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR)"

A GLP‑1 receptor is a protein on certain cells that responds to the hormone GLP‑1, helping control blood sugar and appetite; drugs that activate this receptor can lower glucose and promote weight loss. Investors watch GLP‑1 receptor (GLP‑1R) drugs because successful medicines targeting it can command large markets, shift treatment standards, and drive sales, regulatory reviews, and partnership or acquisition activity — like finding a better key for an important lock.

gcgr medical

"a novel dual agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR)"

GCGR is the cell-surface protein that binds the hormone glucagon, acting like a lock that opens when glucagon — a signal that raises blood sugar — fits into it. It matters to investors because medicines that block or activate this receptor are central to treatments for diabetes and metabolic disease, so progress, safety results, or regulatory decisions about GCGR-targeting drugs can strongly affect a drug developer’s value and future revenue prospects.

gpr119 medical

"vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist"

GPR119 is a specific protein on cells in the gut and pancreas that acts like a light switch for hormones that help lower blood sugar and control appetite. Drug makers study molecules that turn this switch on because doing so can boost natural hormone signals that improve glucose control and reduce eating, so progress in GPR119-targeted drugs can affect the potential market, development risk, and future revenue for companies pursuing diabetes or obesity treatments.

thrβ medical

"combined targeting of GPR119 and thyroid hormone receptor beta (THRβ) for MASH"

A thyroid hormone receptor beta (THRβ) is a protein inside cells that binds thyroid hormones and helps control genes that regulate metabolism, cholesterol, and liver function. For investors, THRβ is important because drugs designed to selectively activate or block this receptor can change how the body processes fats and energy, making it a common target in treatments for metabolic and liver diseases; progress in trials, approvals, or licensing around THRβ-targeting drugs can materially affect a biotech company’s value.

peptide yy medical

"increases in total GLP-1 and peptide YY (PYY) levels of 6.4-fold and 1.5-fold"

Peptide YY is a small hormone released by the gut after eating that helps reduce appetite and slow how quickly the stomach empties, acting like a natural thermostat for hunger. Investors care because drugs or diagnostics that mimic, block, or measure this hormone can become treatments for obesity, diabetes or related conditions, affecting a company’s clinical pipeline, regulatory prospects and potential market size.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau

Vanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Weight-Loss Effects in Preclinical MASH Model

Vanoglipel Combined with Metformin Demonstrated Enhanced Glycemic Control and Body Weight Reduction Versus Monotherapy in a Preclinical T2D Model

CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Association's (ADA) 2026 Scientific Sessions, held June 5–8 in New Orleans, Louisiana. The presentations included new Phase 1 higher-dose cohort results for DA-1726, a novel dual agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), as well as preclinical data supporting combination treatment potential for vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist, in metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2D) and obesity.

The data highlighted favorable safety, tolerability and clinically meaningful reductions in body weight and waist circumference for DA-1726 at the 48 mg dose level, while the vanoglipel presentations demonstrated synergistic metabolic, liver-related effects and weight loss when combined with current standards of care, supporting potential combination strategies across MASH, T2D and obesity.

"The late-breaking ADA 2026 data further reinforces the differentiated and complementary potential of our cardiometabolic pipeline," said Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "DA-1726 demonstrated clinically meaningful and progressive weight loss up to 9.1% at the 48 mg dose level without evidence of plateau, along with consistent reductions in waist circumference and BMI in a once-weekly regimen without titration. Importantly, the data also demonstrates a sustained and progressive metabolic effect through Day 54, supporting continued advancement of higher-dose evaluation in our ongoing Phase 1 Part 3 titration studies designed to assess higher-dose exposure and durability of metabolic response, with results expected in the fourth quarter of 2026."

"In parallel, preclinical vanoglipel combination data demonstrated synergistic effects across liver and metabolic disease models, including meaningful improvements in hepatic steatosis, liver injury markers, fibrosis-related biomarkers, glycemic control, and body weight. Importantly, when combined with resmetirom, vanoglipel's ability to unlock synergistic benefits highlights its potential as a combination strategy for MASH. In addition, when combined with metformin, vanoglipel improved glycemic control and reduced body weight to a greater extent than either monotherapy, further supporting its potential as a therapeutic combination strategy for additional metabolic benefit in T2D. Taken together, these findings further support DA-1726 as a differentiated obesity therapy and vanoglipel as a versatile metabolic backbone for combination approaches in MASH and type 2 diabetes."

• Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results
• Presenting Author: Weikai "Chris" Fang, Chief Medical Officer, MetaVia
• Abstract Control Number: 3102-LB
• Session: 23-B Obesity—Human

The late-breaking poster presentation of DA-1726 reported interim results from a randomized, double-blind, placebo-controlled Phase 1 multiple ascending dose study evaluating once-weekly subcutaneous administration in obese but otherwise healthy adults. In the 48 mg cohort, DA-1726 was generally well tolerated, with predominantly mild-to-moderate and transient gastrointestinal adverse events and no treatment-related discontinuations or serious adverse events. Pharmacokinetic (PK) analysis demonstrated sustained exposure with dose-proportional behavior.

DA-1726 produced a 6.1% reduction in body weight at Day 26 and a 9.1% reduction at Day 54 (p<0.05 vs placebo at Day 26), with continued reductions through Week 8 and no evidence of plateau. Waist circumference was reduced by 5.8 cm at Day 22 and 9.8 cm at Day 54 (p<0.05 vs placebo), with accompanying reductions in BMI of 2.3 kg/m² and 3.4 kg/m² at Day 22 and Day 54, respectively. These clinically meaningful, statistically significant body weight reductions at higher doses were consistent with the dose-proportional PK profile and support continued development for obesity.

• Title: Synergistic Hepatoprotective and Weight-Loss Effects of Vanoglipel and Resmetirom Combination Therapy in a Diet-Induced Obese, Biopsy-Confirmed Mouse Model of MASH
• Presenting Author: Yuna Chae, Lead Research Scientist, Dong-A ST Research Center
• Abstract Control Number: 3043-LB
• Session: 22-C Integrated Physiology—Liver

The late-breaking preclinical study evaluating vanoglipel in combination with resmetirom demonstrated synergistic hepatoprotective and weight-loss effects in a biopsy-confirmed diet-induced obese mouse model of MASH. While monotherapies had no significant effect on body weight, combination treatment achieved a 23.6% reduction versus control (p<0.05), with endpoint fat mass and epididymal fat weight reduced by 43.5% and 42.1%, respectively. All treatments decreased ALT, with the largest reduction rate of 83.5% in the combination group. Histopathologic assessment showed significant improvements in hepatic lipid accumulation, inflammation and fibrosis-related biomarkers. The study represents the first demonstration of the therapeutic potential of combined targeting of GPR119 and thyroid hormone receptor beta (THRβ) for MASH.

• Title: Synergistic Effects of Vanoglipel and Metformin on Glycemic Control and Body Weight Reduction in a Diet-Induced Obese Mouse Model
• Presenting Author: Tae Hyoung Kim, Lead Research Scientist, Dong-A ST Research Center
• Abstract Control Number: 2856-LB
• Session: 12-D Clinical Therapeutics—Other Therapeutic Agents

The late-breaking preclinical study evaluating vanoglipel in combination with metformin demonstrated greater metabolic and weight effects than either monotherapy in a diet-induced obese mouse model with mild hyperglycemia. Combination treatment reduced non-fasting glucose by 28.7% (p<0.05) and fasting glucose by 22.7% versus control. While each monotherapy reduced body weight by approximately 4%, the combination achieved a 16.3% reduction versus control (p<0.05). Fat mass increased by 0.4-1.4 g from baseline in the control and monotherapy groups but decreased by 3.6 g in the combination group (-25.6% vs baseline, p<0.05). These effects were accompanied by increases in total GLP-1 and peptide YY (PYY) levels of 6.4-fold and 1.5-fold, respectively, along with reduced food intake, supporting enhanced gut hormone–mediated metabolic activity.

A copy of the posters will be available on the Posters section of the MetaVia website after the presentation.

About DA-1726
DA-1726 is a novel GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in preclinical mice models, resulted in improved weight loss compared to semaglutide (Wegovy^®), a leading GLP-1 receptor agonist. Additionally, in preclinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared to tirzepatide (Zepbound^®) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.

About Vanoglipel (DA-1241)
Vanoglipel is a once daily, orally available G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the pancreas stimulates glucose-dependent insulin secretion, and in the gut, it promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. Vanoglipel has beneficial effects on glucose, lipid profile and liver pathology including steatosis, inflammation and fibrosis, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of vanoglipel has been demonstrated in multiple animal models of MASH and T2D where vanoglipel reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase 1a and 1b trials, vanoglipel was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). In preclinical studies, vanoglipel demonstrated a positive metabolic effect on glucose and lipid control, and also proved differentiated hepatic benefits reducing hepatic steatosis, hepatic inflammation, and liver fibrosis regardless independent of metabolic improvement. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of preclinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-presents-new-late-breaking-obesity-and-metabolic-data-at-the-ada-2026-scientific-sessions-supporting-da-1726-differentiation-and-vanoglipel-combination-potential-302793358.html

SOURCE MetaVia Inc.

FAQ

What obesity results did MetaVia (MTVA) report for DA-1726 at ADA 2026?

MetaVia reported that DA-1726 48 mg produced up to 9.1% mean body weight reduction by Day 54. According to MetaVia, this once-weekly regimen also reduced waist circumference by 9.8 cm and BMI by 3.4 kg/m², with continued effects through Week 8.

How much weight loss did DA-1726 48 mg achieve in the Phase 1 trial for MTVA?

DA-1726 48 mg led to 6.1% mean body weight loss at Day 26 and 9.1% at Day 54. According to MetaVia, reductions continued through Week 8 without evidence of plateau, alongside dose-proportional pharmacokinetics and consistent waist and BMI declines.

What did vanoglipel plus resmetirom show in MetaVia’s preclinical MASH model?

The vanoglipel–resmetirom combination achieved 23.6% body weight reduction versus control in a MASH mouse model. According to MetaVia, it cut fat mass by 43.5%, epididymal fat by 42.1%, lowered ALT by 83.5%, and improved hepatic lipid, inflammation and fibrosis-related biomarkers.

How did vanoglipel combined with metformin perform in MetaVia’s preclinical T2D model?

Vanoglipel plus metformin reduced non-fasting glucose by 28.7% and fasting glucose by 22.7% versus control. According to MetaVia, the combo delivered 16.3% body weight loss, a 25.6% fat-mass decrease from baseline, higher GLP-1 and PYY levels, and lower food intake.

What safety findings were reported for DA-1726 48 mg in MetaVia’s Phase 1 study?

DA-1726 48 mg was generally well tolerated, with mainly mild-to-moderate, transient gastrointestinal adverse events. According to MetaVia, there were no treatment-related discontinuations or serious adverse events, and pharmacokinetics showed sustained exposure with dose-proportional behavior in obese but otherwise healthy adults.

When are the next DA-1726 higher-dose data expected for MetaVia (MTVA) investors?

MetaVia expects results from ongoing DA-1726 Phase 1 Part 3 titration studies in the fourth quarter of 2026. According to MetaVia, these studies are designed to evaluate higher-dose exposure and durability of metabolic response, building on the 48 mg cohort findings.

How could MetaVia’s vanoglipel combinations impact future MASH and T2D treatment strategies?

Preclinical data suggest vanoglipel may serve as a metabolic backbone in combination regimens for MASH and T2D. According to MetaVia, combinations with resmetirom and metformin improved liver markers, glycemic control, body weight and fat mass, supporting further exploration of these strategies.